Aerovate Therapeutics (NASDAQ:AVTE) Stock Rating Reaffirmed by Wedbush
Wedbush reiterated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $41.00 price target on the stock. Other analysts also recently issued reports about the stock. Jefferies Financial Group initiated coverage on shares of Aerovate Therapeutics in […]